Peer-reviewed veterinary case report
Antibiotic resistance affects treatment success in Boxer dogs
By Craven, M et al.·Published in Journal of veterinary internal medicine·2010·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Antimicrobial resistance impacts clinical outcome of granulomatous colitis in boxer dogs.
- Species:
- dog
Plain-English summary
A group of 14 Boxer dogs with granulomatous colitis (a type of intestinal inflammation) were found to have high levels of antibiotic-resistant E. coli bacteria in their intestines. These resistant strains made it harder for the dogs to recover, especially if they had received certain antibiotics like enrofloxacin before their condition was diagnosed. The study suggests that veterinarians should perform specific tests to determine the best antibiotics for treatment instead of relying on general guidelines. With the right approach, dogs can achieve better outcomes in managing this condition.
People also search for: Boxer dog granulomatous colitis treatment · antibiotic resistance in dogs · E. coli infection in dogs
Abstract
BACKGROUND: Escherichia coli have recently been identified within the colonic mucosa of Boxer dogs with granulomatous colitis (GC). Eradication of invasive E. coli is associated with clinical and histological remission. OBJECTIVES: To determine antimicrobial susceptibility profiles of E. coli strains from GC and healthy dogs, and the association of antimicrobial resistance with clinical outcome. ANIMALS: Fourteen Boxer dogs with GC and 17 healthy pet dogs. METHODS: Prospective study: E. coli was cultured from GC biopsies and rectal mucosal swabs of healthy dogs. Individual strains were selected by phylogroup and overall genotype, determined by triplex- and random amplified polymorphic DNA-polymerase chain reaction respectively. Antimicrobial susceptibility was determined by broth microdilution minimal inhibitory concentration. RESULTS: Culture yielded 23 E. coli strains from GC (1-3/dog, median 2) and 34 strains from healthy (1-3/dog, median 2). E. coli phylogroups were similar (P=.18) in GC (5A, 7B1, 5B2, 6D) and healthy (2A, 10B1, 15B2, 7D). Resistance to ampicillin, amoxicillin-clavulanate, cefoxitin, tetracycline, trimethoprim-sulfa (TMS), ciprofloxacin, and chloramphenicol was greater (P<.05) in GC (21-64%) than healthy (0-24%). Enrofloxacin resistant E. coli were isolated from 6/14 GC versus 0/17 healthy (P=.004). Of the enrofloxacin resistant cases, 4/6 were also resistant to macrophage-penetrating antimicrobials such as chloramphenicol, rifampicin, and TMS. Enrofloxacin treatment before definitive diagnosis was associated with antimicrobial resistance (P<.01) and poor clinical outcome (P<.01). CONCLUSIONS AND CLINICAL IMPORTANCE: Antimicrobial resistance is common among GC-associated E. coli and impacts clinical response. Antimicrobial therapy should be guided by mucosal culture and antimicrobial susceptibility testing rather than empirical wisdom.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20492483/